Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling [Affymetrix]
Ontology highlight
ABSTRACT: In the field of MDS and on bone marrow mononuclear cells , we search for a signature which predict the response to Lenalidomide treatment. This transcriptome study appended to the GFM-LEN-EPO-2008 clinical trial reports a predictive signature of response to lenalidomide and a unique immune response signature after treatment.
ORGANISM(S): Homo sapiens
PROVIDER: GSE102976 | GEO | 2017/08/24
REPOSITORIES: GEO
ACCESS DATA